Why Modern Medicine Is Running Out of Working Antibiotics

In 2018, a biotechnology company called Achaogen achieved what many in the scientific community considered a miracle. After spending 15 years and $1 billion in research and development, it won approval from the Food and Drug Administration (FDA) for plazomicin, a breakthrough antibiotic designed to fight multidrug-resistant infections.

By 2019, Achaogen was bankrupt.

The company’s collapse was not a failure of science, but a failure of the market. Plazomicin worked too well. Because the drug was so powerful, clinical guidelines recommended reserving it for only the most desperate cases to prevent bacteria from developing resistance to it. Limited use resulted in limited sales. For Achaogen, the reward for developing a critical tool for modern medicine was a total lack of revenue.

This paradox is currently hollowing out the foundation of modern healthcare. While cancer treatments and rare-disease drugs can command high prices and high volume, antibiotics—the literal safety net for surgery, chemotherapy, and childbirth—are a financial graveyard. The market for these drugs is broken because the fundamental business model punishes the successful development of products meant for conservative use.

The Math of Market Failure

To understand why the medicine cabinet is going bare, one must look at the arithmetic of pharmaceutical investment. Developing a new antibiotic today costs an estimated $1.5 billion. However, because of the necessary push for “stewardship”—the practice of using new drugs sparingly to avoid breeding superbugs—the average annual revenue for a new antibiotic is a mere $46 million.

Source: AMR Action Fund / Eastern Association for the Surgery of Trauma

This discrepancy creates a Net Present Value (NPV) of negative $50 million for investors, according to data from the AMR Action Fund. In the logic of institutional finance, an investment that is projected to lose money is often disregarded in favor of more lucrative sectors. According to CARB-X, the current “fire extinguisher” model of antibiotic procurement—where manufacturers are only compensated when the drug is used during a crisis—fails to provide the predictable returns necessary to sustain long-term R&D.

The result is a shift in intellectual capital and resource allocation. By 2024, the AMR Industry Alliance noted that there were 20 times more patents awarded for cancer innovations than for antibiotics. Investment is flowing away from infectious disease and toward sectors like oncology or aesthetics, where the path to profitability is more certain.

A Shrinking Pipeline in a Growing Storm

The timing of this exodus is critical. Antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths globally in 2019. By 2050, that number is projected to climb to 1.91 million deaths annually if the pipeline is not revitalized, according to 2024 projections in the Journal for Global Business and Community.

Yet, the tools available to fight back are dwindling. The number of antibacterial agents in clinical development fell from 97 in 2023 to 90 by late 2024, according to the World Health Organization (WHO). Even more alarming is the quality of what remains: the WHO reports that only five antibiotics in the current pipeline target “critical” pathogens, the most dangerous drug-resistant bacteria on the planet.

Low-and-middle-income countries are already facing the brunt of this shortage. Approximately 80 percent of global AMR deaths occur in these regions, where access to newer, more effective drugs is often years behind Western markets. According to the UK’s Review on Antimicrobial Resistance, the global economic impact of uncontrolled AMR could reach $100 trillion by 2050.

The Global Experiment in ‘Subscription’ Economics

Governments are beginning to realize that the traditional “pay-per-pill” model cannot sustain antibiotic development. To save the sector, they are experimenting with “pull incentives”—payments that decouple a company’s profit from the volume of drugs they sell.

In 2022, the United Kingdom pioneered what has become known as the “Netflix model.” Under this system, the National Health Service (NHS) pays pharmaceutical companies a fixed annual fee—up to £10 million per drug—for access to new antibiotics. It does not matter if a doctor uses the drug once or a thousand times; the company receives the same guaranteed revenue. This allows the NHS to keep the best drugs on the shelf for emergencies without bankrupting the manufacturers.

Other nations are following suit with their own variations. Sweden implemented a “Revenue Guarantee” model, ensuring manufacturers receive a minimum of approximately €400,000 per year just to maintain the availability of critical treatments. In 2024, Japan increased the budget for its antimicrobial procurement pilot to 1.3 billion Yen (about $9 million) to secure supplies of last-line treatments for resistant infections.

Meanwhile, the European Union is debating a Transferable Exclusivity Extension (TEE). This would grant a company that develops a new antibiotic a one-year patent extension on a different, highly profitable drug in their portfolio. While this would cost governments nothing upfront, analysis suggests it could function as a significant cost to patients and insurers by delaying the arrival of cheaper generic drugs for blockbuster medications.

The American Standoff

In the United States, the legislative focus is on the PASTEUR Act. Reintroduced in 2024 by Senators Michael Bennet (D-CO) and Todd Young (R-IN), the bipartisan bill proposes $6 billion in federal funding to establish a subscription model similar to the UK’s.

The logic is that by providing a predictable, multi-year revenue stream, the U.S. government can de-risk the sector and entice venture capital back into antibiotic R&D. Proponents argue the $6 billion price tag is a bargain compared to the $4.6 billion in direct healthcare costs that drug-resistant infections add to the U.S. economy annually.

However, the bill faces opposition regarding its long-term implementation. Data from Doctors Without Borders (MSF) suggests that the PASTEUR Act requires more robust guardrails to ensure that resulting medicines remain affordable and accessible once they reach the market.

A significant hurdle remains within the current Medicare reimbursement system. Under the Diagnosis Related Group (DRG) system, hospitals receive a fixed, prospective payment for a patient’s entire stay based on their diagnosis. If a physician prescribes a new, innovative antibiotic costing $2,000 per course over a $20 generic, the hospital must absorb that $1,980 difference entirely.

For a hospital CFO managing tight margins, these “uncompensated” costs for superior drugs create a systemic disincentive. A surgical procedure that would otherwise be profitable for the hospital can quickly become a financial loss if a drug-resistant infection necessitates the use of premium, brand-name antibiotics. This “hidden” financial pressure often keeps the most effective new drugs out of hospital pharmacies, even when they are clinically superior.

Why This Matters for the Average American

The antibiotic crisis is often framed as a niche concern, but the broken pipeline threatens the entire architecture of modern life. Antibiotics have extended human life expectancy by an average of 23 years, according to 2024 data from the World Economic Forum. Without them, the risks of routine procedures skyrocket.

Consider the impact on a 30-year-old patient with a standard urinary tract infection. In a clinical environment with effective antibiotics, this is a three-day course of oral pills. However, with the rise of resistant strains, such an infection can lead to multiple hospitalizations, weeks of intravenous therapy, and the constant threat of sepsis from an infection once considered a minor inconvenience.

Cancer patients are among the most vulnerable. According to 2024 clinical data, roughly 50 percent of deaths in patients with certain blood cancers are associated with infections, many of which are now resistant to standard treatments. We are entering an era where a patient might survive aggressive chemotherapy only to succumb to a common infection caught during a hospital stay.

“We are seeing a paradox where the drugs we need most for public health are the ones that have the least viable commercial path,” according to the AMR Action Fund.

The Turn Toward Resilience

The exodus of large pharmaceutical firms from the sector has left the majority of innovation to small and medium-sized enterprises (SMEs). Today, these smaller firms lead over 90 percent of the preclinical antibiotic pipeline. But as the Achaogen story proved, being a small firm with a successful drug is a precarious position. Without a structural change in how society pays for these medicines, the remaining projects in the global pipeline face significant commercial headwinds.

There are signs of a shift. The AMR Action Fund, a $1 billion initiative backed by 20 pharmaceutical companies, aims to bring two to four new antibiotics to market by 2030. However, the organization notes that private philanthropy and industry-led funds are temporary measures, not permanent solutions.

As World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus has stated, the global health community needs a new business model that decouples the volume of sales from the investment in development.

The reality is that the market struggles to manage resources that are intended primarily for emergency readiness. Solving the antibiotic crisis will require treating these drugs not as standard consumer goods, but as essential infrastructure—something that must be funded and maintained for its availability, not its daily utilization. The choice facing governments and investors is whether to pay for the “fire extinguisher” now, or face the rising costs of a healthcare system without its most fundamental safety net.